



## Continuing Education Activity

**Activity Number:** WE-E04262012

**Title:** Avoiding Adverse Medication Events

**Presented by:** Dr. Daniel Budnitz, Director of the Medication Safety Program of the Division of Healthcare Quality Promotion, at the Centers for Disease Control (CDC); Dr. Kyle Campbell, Project Director for the Centers for Medicare and Medicaid Services (CMS) Maintenance and Development Medication Measures Special Project at FMQAI, the Medicare Quality Improvement Organization (QIO) for Florida; Dr. Almut Winterstein, Associate Professor & Graduate Program Coordinator, Department of Pharmaceutical Outcomes and Policy, University of Florida

Date: April 26, 2012  
Estimated Time: 1 Hour  
Course Format: In-person Presentation  
Course Fee: Free

**Activity Goal/Description:** The overall goal of this activity is to inform CMS staff, contractors and others about policies developed by CMS, new trends in health care, and the constantly evolving medical industry. This informational series will provide the foundation for the participant to support health care policy and program development, implementation and review at a level of excellence.

**Target Audience:** Physicians and other Health Care Professionals

**Activity Learning Objective:** By the end of the presentation, you should be able to recognize the scope and importance of adverse drug events, and review CMS medication measure development progress.

### Instructions for Participation and Credit:

In order to receive continuing education credit, participants must:

1. Attend the live presentation (in person, via VTC or Meeting Place) or view the online presentation
2. Submit the post activity evaluation, which is automatically generated after closing the completed WebEx session
3. Successfully complete the course by passing the post activity assessment, which is located at the end of the post activity evaluation

Note: Links to the post activity evaluation and post activity assessment will be forwarded to live activity participants via e-mail and are located at the end of this document. Participants will be notified whether or not they successfully completed the session within 30 days of registering. Certificates will be issued electronically after successful completion of the course. Those participants that did not successfully complete the post activity evaluation and post activity assessment can register for the session again and attempt to earn continuing education credit by taking the assessment again.

**Activity Credit:****Accreditation Council for Continuing Medical Education (ACCME)**

## ACCME Accreditation Statement

The Centers for Medicare & Medicaid Services (CMS) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

## ACCME Designation Statement

The Centers for Medicare & Medicaid Services designates this enduring material for a maximum of *1 AMA PRA Category 1 Credit™*. Physicians should only claim credit commensurate with the extent of their participation in the activity. Credit for this course expires April 26, 2015.

**IACET International Association for Continuing Education and Training (IACET)**

## IACET Accreditation Statement

The Centers for Medicare & Medicaid Services (CMS) has been approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 8405 Greensboro Drive, Suite 800, McLean, VA 22102. In obtaining this approval, CMS has demonstrated that it complies with the ANSI/IACET Standards which are widely recognized as standards of good practice internationally. As a result of their Authorized Provider membership status, CMS is authorized to offer IACET CEUs for its programs that qualify under the ANSI/IACET Standards.

## IACET Designation Statement

The Centers for Medicare & Medicaid Services (CMS) is authorized by IACET to offer *0.1 CEU* for this program. CEU will be awarded to participants who meet all criteria for successful completion of this enduring material. CEU credit for this course expires April 26, 2015.

**Authors and Disclosures:**

No one in a position to control the content of this activity has anything to disclose. All planners and developers of this activity have signed a disclosure statement indicating that they have no relevant financial interests. This activity was developed without commercial support. Please see developer and presenter bios below.

Daniel Budnitz (developer/presenter) is Director of the Medication Safety Program of the Division of Healthcare Quality Promotion, CDC. He has authored over 35 publications on medication safety monitoring, using national data to target safety measures, and applying lessons from injury prevention to drug safety.

Dr. Budnitz received a BA (Government) from Harvard University, and a combined MD/MPH (Epidemiology) from Emory University. After completing residency training in internal medicine at the Hospital of the University of Pennsylvania, he served as an Epidemic Intelligence Service (EIS) Officer with CDC's Injury Center.

Dr. Budnitz is currently a Captain in the US Public Health Service, Clinical Assistant Professor of Internal Medicine, Emory University, and has practiced as a Board-certified internist at the Atlanta VA Medical Center and the DeKalb-Grady Neighborhood Health Center.

Kyle Campbell (developer/presenter) is the Project Director for the Centers for Medicare & Medicaid Services (CMS) Maintenance and Development of Medication Measures Special Project at FMQAI, the Medicare Quality Improvement Organization (QIO) for Florida. Under Dr. Campbell's direction, the project's initiatives have resulted in a portfolio of five National Quality Forum-endorsed measures, three of which have been implemented in various CMS reporting programs. In addition, the project has new medication measures under development for the hospital and ambulatory care settings. In other roles at FMQAI, Dr. Campbell managed a patient and medication safety initiative for critical access hospitals for the Florida Department of Health and was instrumental in the design of Florida's successful drug safety project under the QIO 9th Statement of Work.

Dr. Campbell's areas of expertise include clinical pharmacy, quality measure development, and design and implementation of quality improvement interventions. He has been invited to give several local, regional, and national presentations related to medication safety and the development of medication-related quality measures. Dr. Campbell received a PharmD from the University of Florida.

Almut Winterstein (developer/presenter) received her pharmacy degree from Friedrich Wilhelm University in Bonn, Germany and her PhD in Pharmacoepidemiology from the Humboldt University in Berlin, Germany. She joined faculty at the University of Florida in 2000 and holds the position of Associate Professor in the Department of Pharmaceutical Outcomes and Policy at the College of Pharmacy, and in the Department of Epidemiology at the Colleges of Public Health and Health Professions and Medicine. She is also director of the FDA/CDER Graduate Program at the University of Florida aimed at training CDER employees in Pharmaceutical Outcomes and Policy Research.

Almut's research interests focus on drug safety and effectiveness, and the evaluation and prevention of inappropriate medication use. Clinical focus areas of pharmacoepidemiologic studies include pediatrics, psychiatry, infectious disease, and diabetes mellitus. Her interest in quality of care issues focuses on the development and evaluation of medication safety programs, clinical decision support systems and quality metrics. Almut has received funding from the FDA, AHRQ, American Society of Health System Pharmacist (ASHP) Research Foundation, the Drug Information Association (DIA), the International Federation of Pharmacy Associations (FIP), and various state agencies including the Florida Department of Health. She serves on the FDA/CDER Drug Safety and Risk Management Advisory Board (DSaRM) and as consultant on medication safety issues for the Florida Department of Rural Health.

**Hardware and Software Requirements:** Computer, Internet/e-mail access

[Privacy Policy](#)

For questions regarding the content of this activity, or for technical assistance contact Jason Pry at [J.Pry@HSAG.com](mailto:J.Pry@HSAG.com) [Tennille.Brown@cms.hhs.gov](mailto:Tennille.Brown@cms.hhs.gov) or [Andria.Charlow@cms.hhs.gov](mailto:Andria.Charlow@cms.hhs.gov) via e-mail.

*AMA PRA Category 1 Credit™ is a trademark of the American Medical Association.*

**To access the activity click on the link below.**

<https://hsag.webex.com/hsag/lsr.php?AT=pb&SP=EC&rID=68108387&rKey=1a599aa92d02fa9e>